informaconnect.com/asia-bio-partnering-forum/

The contents page for IPT Summer 2025!

www.carbogen-amcis.com/sterile-drug-product-cdmo

Summer is upon us, and with the warm weather comes inspiration for innovations in all areas, particularly pharmtech. This edition of IPT includes fascinating discussions around manufacturing different materials for pharma treatments, such as synthetic DNA (4basebio, page 14) and gene therapies (FinVector Oy, page 18), and how the sector can improve green ideas to ensure more sustainable production (Syntegon Technology, page 22).

BIOEUROPE.COM

IPT highlights some of the most recent exciting advancements in pharmaceutical manufacturing

1-3 July 2025, Manchester, UK

Tablet formulation development often uses small R&D tablet presses to optimise both the composition of the formulation and manufacturing process parameters. These types of machines have a wide variety of capabilities and may be either single station or small rotaries.

Why is the use of synthetic DNA a better choice for emerging genetic medicines?

What are some innovative techniques used for manufacturing gene therapies at a commercial scale?

Sustainability is top of the agenda for many pharmaceutical manufacturing companies. Which role do technology providers and their equipment play in reducing CO2 emissions

INTERPHEX 2025, the leading global trade event for pharmaceutical and biotechnology professionals, concluded with resounding success after three days (1-3 April 2025) at the Javits Center, New York, US. This year’s event brought together nearly 10,000 industry professionals representing all stages of the pharmaceutical product development life cycle. With over 550 exhibitors, cutting-edge innovations and countless opportunities for meaningful engagement, INTERPHEX 2025 proved

www.iptonline.com

Computational drug discovery relies on two major approaches: ligand-based drug design and structure-based drug design. This article discusses the principles, techniques and applications of both methodologies, as well as a combined approach; providing insights into when to use each method and highlighting complementary insights provided by the two approaches

Targeted drug delivery to the liver is essential for treating a range of liver-related diseases, including viral hepatitis, liver cancer and metabolic disorders. However, conventional therapies often suffer from poor specificity, leading to off-target effects and suboptimal therapeutic outcomes. GalNAc (N-acetylgalactosamine) conjugates offer a promising solution as they provide a selective, efficient method of reaching hepatocytes, making them a valuable tool in modern thera

https://posummit.com/

From accelerating drug discovery to enabling earlier cancer diagnosis, how is artificial intelligence redefining value creation, transforming patient care and prompting a shift from reactive treatment to proactive intervention?

What’s the evolving impact of digitalisation on life sciences operations, and how can a systems-engineered approach help to create more resilient, flexible and future-ready compliant thermal processes?

For decades, bringing a drug from concept to patient access has been an expensive, convoluted and often uncertain journey. The traditional drug discovery process relies heavily on trial and error, biological hypotheses and rigid scientific processes. Various challenges significantly prolong the drug discovery process, ultimately slowing the pace of innovation and delivery of treatment for patients. Today, the integration of artificial intelligence into the drug discovery proc

Retrosynthesis is the chemist’s toolkit for building complex molecules from simpler ones. Once rooted in intuition and experience, the process has been transformed by artificial intelligence and big data. This article explores how retrosynthesis works, why it matters and how it’s shaping the future of chemistry – from drug discovery to materials science

https://biomanamerica.com/

As the need for ultra-low temperature sample storage rises, many labs are stuck expanding outdated ‘freezer farms’ to meet demand. High-density automated cold storage offers a smarter, more efficient solution, but reaping the benefits depends on more than the technology itself – it requires thoughtful change management. How can companies approach change management to drive lasting adoption and maximise the value of automation?

In an era of cost-conscious innovation, including tighter budgets, talent shortages and escalating regulatory demands, life sciences labs are under pressure to improve performance while managing budgets more wisely. By focusing on equipment utilisation and asset intelligence, labs can reduce downtime, avoid unnecessary purchases, optimise maintenance intervals and scale smarter – all without compromising quality or compliance

WWW.FLYPHARMAEUROPE.COM

A collation of the top Pharma events for summer 2025!

https://biomaneurope.com/

www.natoli.com/ez-level